Brief: Nabriva Therapeutics Reports Fourth Quarter Revenue Of $9.3 Mln
29/03/2022 21:21
March 29 (Reuters) - Nabriva Therapeutics PLC NBRV.O :
* NABRIVA THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR
2021
FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE
* Q4 REVENUE $9.3 MILLION
* CASH RUNWAY EXTENDED WELL INTO Q4 2022
* QTRLY LOSS PER SHARE BASIC AND DILUTED $0.24
Source text for Eikon: ID:nGNX62DM7V
Further company coverage: NBRV.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nabriva Therapeutics
See all newsBrief: Nabriva Therapeutics And Units Enter Asset Purchase Agreement With Sumitomo Pharma
Brief: Nabriva Therapeutics Says Received Delisting Determination Letter From Nasdaq
Brief: Nabriva Therapeutics Receives Notice Of Delisting Or Failure To Satisfy Continued Listing Rule From Nasdaq
Brief: Nabriva Therapeutics - On Jan 31, Co's Unit Entered Into Letter Agreement With 2 Units Of Merck & Co, About Distribution Agreement, Dated July 15, 2020
Brief: Nabriva Therapeutics Provides Corporate Update